Core Viewpoint - Tenet Healthcare (THC) has shown strong stock performance recently, with an 8.1% return over the past month, outperforming the S&P 500's 2.7% and the Zacks Medical - Hospital industry's 4.3% [1] Earnings Estimates - Tenet is expected to report earnings of $3.35 per share for the current quarter, reflecting a year-over-year increase of 14.3% [4] - The consensus earnings estimate for the current fiscal year is $15.54, indicating a year-over-year change of 30.8% [4] - For the next fiscal year, the consensus estimate is $15.96, showing a 2.7% increase from the previous year [5] Revenue Growth - The consensus sales estimate for the current quarter is $5.25 billion, representing a year-over-year change of 2.4% [10] - Estimated revenues for the current and next fiscal years are $21.15 billion and $22.14 billion, indicating changes of 2.4% and 4.6%, respectively [10] Recent Performance - In the last reported quarter, Tenet achieved revenues of $5.27 billion, a year-over-year increase of 3.3% [11] - The EPS for the same period was $4.02, compared to $2.31 a year ago, with a revenue surprise of 2.42% and an EPS surprise of 41.55% [11][12] Valuation - Tenet is graded A in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [16] - The evaluation of valuation multiples such as P/E, P/S, and P/CF suggests that Tenet's stock is fairly valued or undervalued relative to its historical values and peers [14][15] Conclusion - The Zacks Rank 2 for Tenet suggests potential outperformance in the near term, supported by strong earnings and revenue growth projections [17]